Last reviewed · How we verify
NCT04480138
Pegylated Interferon - α2b With SARSCoV- 2 (COVID-19)
Phase 2 trial testing Pegylated Interferon-α2b in Covid19 in 7 participants. Terminated before completion.
21 June 2021
Quick facts
| Lead sponsor | Zydus Lifesciences Limited |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 7 |
| Start date | 11 August 2020 |
| Primary completion | 21 June 2021 |
| Estimated completion | 21 June 2021 |
| Sites | 2 locations across Mexico |
Drugs / interventions tested
- Pegylated Interferon-α2b — full drug profile →
- Standard of Care
Conditions studied
- Covid19 — all drugs for Covid19 →
Sponsor
Zydus Lifesciences Limited — full company profile →
Who can join
18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a phase II, multicenter, open-label, randomized, comparator-controlled study to evaluate the efficacy and safety of Pegylated Interferon -α2b in the treatment of adult patients diagnosed with SARS-CoV2 (COVID-19).Initial 1 mcg/kg of Pegylated Interferon-α2b will be administered on day 1. After safety evaluation of first dose, next dose (second dose) 1 mcg/kg on day 8 will be administered with recommended standard care during the trial.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Inflammatory pathways in COVID-19: Mechanism and therapeutic interventions.
Jiang Y, Zhao T, Zhou X, Xiang Y, et al · · 2022 · cited 44× · PMID 35923762 · DOI 10.1002/mco2.154 -
Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β.
Vinh DC, Abel L, Bastard P, Cheng MP, et al · · 2021 · cited 40× · PMID 34101091 · DOI 10.1007/s10875-021-01068-6 -
Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer.
Elkrief A, Wu JT, Jani C, Enriquez KT, et al · · 2022 · cited 33× · PMID 34893494 · DOI 10.1158/2159-8290.cd-21-1368 -
Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19.
Ni Y, Alu A, Lei H, Wang Y, et al · · 2021 · cited 20× · PMID 34766001 · DOI 10.1186/s43556-020-00015-y -
Roles of Type I and III Interferons in COVID-19.
Choi H, Shin EC. · · 2021 · cited 20× · PMID 33908208 · DOI 10.3349/ymj.2021.62.5.381 -
Revisiting Pleiotropic Effects of Type I Interferons: Rationale for Its Prophylactic and Therapeutic Use Against SARS-CoV-2.
Garcia-Del-Barco D, Risco-Acevedo D, Berlanga-Acosta J, Martos-Benítez FD, et al · · 2021 · cited 16× · PMID 33841439 · DOI 10.3389/fimmu.2021.655528 -
Myeloid dysregulation and therapeutic intervention in COVID-19.
Gu R, Mao T, Lu Q, Tianjiao Su T, et al · · 2021 · cited 13× · PMID 34823995 · DOI 10.1016/j.smim.2021.101524 -
Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment.
Zou H, Yang Y, Dai H, Xiong Y, et al · · 2021 · cited 12× · PMID 34880750 · DOI 10.3389/fphar.2021.732403
Verify or expand the search:
- PubMed search for NCT04480138
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other Zydus Lifesciences Limited trials
Trials by the same sponsor.
- NCT05911828 — A Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combina · Phase 1 · recruiting
- NCT06398808 — A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately · Phase 2 · completed
- NCT05981040 — Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Scl · Phase 2 · completed
- NCT05872269 — A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities · Phase 4 · unknown
- NCT05515367 — A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04480138 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zydus Lifesciences Limited
- Last refreshed: 12 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04480138.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing